The matrix metalloproteinase system in oral squamous cell carcinoma
- PMID: 16338034
- DOI: 10.1016/j.bjoms.2005.10.005
The matrix metalloproteinase system in oral squamous cell carcinoma
Abstract
Background: The matrix metalloproteinase (MMP) system is responsible for degradation of tissue in both normal and pathological processes, including tumour invasion and metastasis.
Aim: To compare tissue concentrations of components of the MMP system between tumour tissue and normal tissue in patients with oral squamous cell carcinoma, and to correlate concentrations with pathological grade of tumour.
Methods: Thirty-eight paired tissue samples from tumours and normal tissue were analysed by three laboratory techniques: firstly, enzyme linked immunosorbent assays (ELISA) in ng/mg protein for MMP-1, MMP-3, and tissue inhibitors of metalloproteinases (TIMPs) -1 and -2. Secondly, gelatinase activity assays to measure concentrations of total and endogenous active gelatinases, MMP-2 and MMP-9 (ng/mg protein). And thirdly to use quenched fluorescent substrate hydrolysis to measure total MMP activity (pM/min).
Results: The concentration of all MMPs was significantly higher in tumour than in normal oral tissue (p < 0.05, Mann-Whitney U-test). Tissue concentrations of some of these factors correlated with clinical and pathological indices of aggressiveness of tumours, including T-stage, N-stage, tumour differentiation, and anatomical level of involved nodes. However, the study was not powered to show statistical significance.
Conclusion: It is the balance between proteinases and their inhibitors that controls tissue degradation at each stage of tumour invasion and metastasis. Measurement of MMPs in oral mucosal biopsy samples may establish the invasive potential of tumours at their initial presentation.
Similar articles
-
Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.Br J Surg. 2000 Sep;87(9):1215-21. doi: 10.1046/j.1365-2168.2000.01531.x. Br J Surg. 2000. PMID: 10971431
-
Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis.J Oral Pathol Med. 2007 Aug;36(7):415-24. doi: 10.1111/j.1600-0714.2007.00546.x. J Oral Pathol Med. 2007. PMID: 17617835
-
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.J Orofac Pain. 2000 Winter;14(1):20-30. J Orofac Pain. 2000. PMID: 11203734
-
Matrix metalloproteinases and their inhibitors.Anticancer Res. 1999 Mar-Apr;19(2C):1589-92. Anticancer Res. 1999. PMID: 10365151 Review.
-
[Extracellular matrix -- from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases].Dtsch Med Wochenschr. 2004 Sep 17;129(38):1976-80. doi: 10.1055/s-2004-831836. Dtsch Med Wochenschr. 2004. PMID: 15375740 Review. German.
Cited by
-
Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction.Biomark Insights. 2007 Oct 8;2:377-84. Biomark Insights. 2007. PMID: 19662219 Free PMC article.
-
Kaempferol reduces matrix metalloproteinase-2 expression by down-regulating ERK1/2 and the activator protein-1 signaling pathways in oral cancer cells.PLoS One. 2013 Nov 20;8(11):e80883. doi: 10.1371/journal.pone.0080883. eCollection 2013. PLoS One. 2013. PMID: 24278338 Free PMC article.
-
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.J Control Release. 2017 Aug 10;259:62-75. doi: 10.1016/j.jconrel.2017.01.034. Epub 2017 Jan 31. J Control Release. 2017. PMID: 28153760 Free PMC article. Review.
-
The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.Integr Biol (Camb). 2018 Apr 23;10(4):253-269. doi: 10.1039/c8ib00019k. Integr Biol (Camb). 2018. PMID: 29623971 Free PMC article.
-
The matrix metalloproteinase and insulin-like growth factor system in oral cancer - a prospective clinical study.Onco Targets Ther. 2017 Oct 24;10:5099-5105. doi: 10.2147/OTT.S149231. eCollection 2017. Onco Targets Ther. 2017. PMID: 29123408 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous